Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD

References

• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J. Hypertens. 25, 1751–1762 (2007).
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Stopping the cardiovascular disease continuum: focus on prevention. World J. Cardiol. 2, 43–49 (2010).
   PubMedGoogle Scholar
• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217–223 (2005).
   PubMed Web of Science ®Google Scholar
• Roger VL, Go AS, Lloyd-Jones et al. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 25, e2–e220 (2012).
   Google Scholar
• Bakris GL, Sowers JR, Giles TD et al. Treatment of hypertension in patients with diabetes – an update. J. Am. Soc. Hypertens. 4, 62–67 (2010).
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Council on Clinical Cardiology and Epidemiology and Prevention. Circulation 115, 2761–2788 (2007).
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Bertoia ML, Waring ME, Gupta PS, Roberts MB, Eaton CB. Implications of new hypertension guidelines in the United States. Hypertension 58, 361–366 (2011).
   PubMed Web of Science ®Google Scholar
• Gradman AH. Rationale for triple combination therapy for management of high blood pressure. J. Clin. Hypertens. 12, 869–878 (2010).
   PubMed Web of Science ®Google Scholar
• Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin. Drug Investig. 28, 713–734 (2008).
   PubMed Web of Science ®Google Scholar
• Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J. Am. Soc. Hypertens. 4, 42–50 (2010).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkanan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120, 713–719 (2007).
   PubMed Web of Science ®Google Scholar
• Panjabi S, Lacey M, Bancroft T, Gao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J. Am. Soc. Hypertens. 7, 46–60 (2013).
   PubMed Web of Science ®Google Scholar
• Oparil S, Chrysant SG, Melino M, Lee J, Karki S, Heyrman R. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a sub study of the COACH trial. J. Hum. Hypertens. 24, 831–838 (2010).
   PubMed Web of Science ®Google Scholar
• Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin. Ther. 32, 1252–1269 (2010).
   PubMed Web of Science ®Google Scholar
• Deeks ED. Olmesartan medoxomil/amlodipine/hydrochlorothiazide fixed-dose combination in hypertension. Drugs 71, 209–220 (2011).
   PubMed Web of Science ®Google Scholar
• Scott LJ, Mc Cormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 68, 1239–1272 (2008).
   PubMed Web of Science ®Google Scholar
• Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 50, 560–566 (1995).
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Weber MA, Wang AC, Hinman DJ. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens. 17, 252–259 (2004).
   PubMed Web of Science ®Google Scholar
• Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur. J. Clin. Pharmacol. 12, 297–303 (1977).
   PubMed Web of Science ®Google Scholar
• Ausubel H, Levine ML. Treatment of hypertension with Ser-Ap-Es. Curr. Ther. Res. Clin. Exp. 9, 29–35 (1967).
   PubMed Web of Science ®Google Scholar
• Moser M. From JNC 1-JNC 7: what have we learned? Prog. Cardiovasc. Dis. 48, 303–315 (2006).
   PubMed Web of Science ®Google Scholar
• Fagan TC. Remembering the lessons of basic pharmacology. Arch. Intern. Med. 1541430–1431 (1994).
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. 328, 914–992 (1993).
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J. Clin. Hypertens. 11, 475–482 (2009).
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther. 30, 587–604 (2008).
   PubMed Web of Science ®Google Scholar
• Izzo JL, Chrysant SG, Kereiakes DJ et al. 24-H efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. J. Clin. Hypertens. 13, 873–880 (2011).
   PubMed Web of Science ®Google Scholar
• Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label long-term study. Clin. Drug Invest. 29, 381–391 (2009).
   PubMed Web of Science ®Google Scholar
• Weir MR, Hsue WA, Nesbitt SD et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixer-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J. Clin. Hypertens. 13, 404–412 (2011).
   PubMed Web of Science ®Google Scholar
• Neutel JM, Smith DHG, Weber MA, Wang AC, Masonson HN. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J. Clin. Hypertens. 6, 168–174 (2004).
   PubMedGoogle Scholar
• Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 54, 32–39 (2009).
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Crikelait N, Glazer RD, Yen J, Calhoun DA. 24-h ambulatory blood pressure control with the triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J. Hum. Hypertens. 25, 615–522 (2011).
   PubMed Web of Science ®Google Scholar
• Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J. Am. Soc. Hypertens. 2, 294–302 (2008).
   PubMed Web of Science ®Google Scholar
• Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND Study. J. Hum. Hypertens. 23, 479–489 (2009).
   PubMed Web of Science ®Google Scholar
• Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: The Exforge in Failure after Single Therapy (EX-FAST) Study. J. Clin. Hypertens. 10, 185–194 (2008).
   PubMed Web of Science ®Google Scholar
• Lacourciere Y, Taddei S, Konis G, Fang H, Severin T, Zhang J. Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. J. Hypertens. 30, 2047–2055 (2012).
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Chrysant SG, Izzo JL et al. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multi center, randomized, double-blind, parallel-group TRINITY study. Cardiovasc. Diabetol. 11, 134 (2012).
   PubMed Web of Science ®Google Scholar
• Oparil S, Chrysant SG, Melino M, Lee J, Karki S, Heyrman R. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil in patients with hypertension stratified by age, race and diabetes: a sub-study of the COACH trial. J. Hum. Hypertens. 24, 831–838 (2010).
   PubMed Web of Science ®Google Scholar
• Yannakopoulou E, Papadopoulos JS, Cokkinos DV, Mantokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur. J. Cardovasc. Rev. Rehabbil. 12, 243–249 (2005).
   Google Scholar
• Fung V, Huang J, Brand R, Newhouse JP, Hsu J. Hypertension treatment in a Medicare population: adherence and systolic blood pressure control. Clin. Ther. 29, 972–984 (2007).
   PubMed Web of Science ®Google Scholar
• Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure lowering drugs and control of aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 113, 1213–1225 (2007).
   Web of Science ®Google Scholar
• Agapiti-Rosei M, Mancia G, O’Rourke MF et al. Central blood pressure measurements and antihypertensive therapy. A consensus document. Hypertension 50, 154–160 (2007).
   PubMed Web of Science ®Google Scholar
• Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, for the OSCAR Study Group. An angiotensin II receptor blocker- calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int. 83, 167–176 (2013).
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM, Gong Y, Hanberg EM et al. Tight blood pressure control on cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304, 61–68 (2010).
   PubMed Web of Science ®Google Scholar
• Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
   PubMed Web of Science ®Google Scholar
• Safar ME, Balkau B, Lange C et al. Hypertension and vascular dynamics in men and women with the metabolic syndrome. J. Am. Coll. Cardiol. 61, 12–19 (2013).
   PubMed Web of Science ®Google Scholar
• Sleight P, Redon J, Verdecchia P et al.; on behalf of the ONTARGET Investigators. Prognostic value of blood pressure in patients with vascular risk. In the Ongoing Telmisartan alone and in Combination with Ramipril Global Endpoint Trial study. J. Hypertens. 27, 1360–1369 (2009).
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agapiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27, 2121–215 (2009).
   PubMed Web of Science ®Google Scholar